Platelet News and Research

RSS

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Adding motesanib to carboplatin–paclitaxel does not boost overall survival in patients with advanced nonsquamous non-small-cell lung cancer, including those with adenocarcinoma, say MONET1 investigators.

8 Aug 2012

Link between maternal metabolic or psychological stress and obesity in offspring

A new report involving mice suggests that a relationship exists between maternal metabolic or psychological stress and the development of obesity, type 2 diabetes, and metabolic syndrome in her offspring. What's more, the report shows that if the stress cannot be reduced or eliminated, manipulating the neuropeptide Y (NPY) system in visceral fat may prevent maternal stress-induced obesity from occurring in the next generation.

1 Aug 2012

Study identifies 329 instances of potentially inappropriate prescribing in Irish older patients

Research published in the journal Age and Ageing, which studied nursing homes in the Munster region of Ireland, has found that a significant proportion of older patients have either been prescribed a potentially inappropriate medicine or they are not prescribed a medicine that would normally be beneficial.

26 Jul 2012

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

24 Jul 2012

Endovascular stroke therapy may prove beneficial in octogenarians

Use of intra-arterial therapy in octogenarian patients with stroke does not appear to increase their risk for dying in hospital above that seen with use of intravenous recombinant tissue plasminogen activator, a large study suggests.

23 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

T2Hemostasis provides reliable and rapid results when compared to conventional systems

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of new data on hemostasis monitoring at the American Association for Clinical Chemistry Annual Meeting, July 15-19, 2012, in Los Angeles, CA.

20 Jul 2012

Medica releases EasyCell solution for hematology laboratories

Medica Corporation, a provider of easy-to-use, low-cost blood testing analyzers, announced today the global release of its EasyCell assistant cell image analyzer for hematology laboratories.

From Medica Corporation 18 Jul 2012

Ticagrelor ‘now on equal footing’ with other antiplatelets

The platelet aggregation inhibitor ticagrelor is now considered of equal effectiveness to clopidogrel and prasugrel for patients who have experienced a heart attack or have unstable angina, a report states.

17 Jul 2012

Ticagrelor ‘now on equal footing’ with other antiplatelets

17 Jul 2012

PRP therapy safe and effective method of treatment for athletes with cartilage tears

When it comes to treating cartilage tears in athletes, Platelet Rich Plasma (PRP) therapy is a safe and effective method of treatment, according to research presented today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in Baltimore.

16 Jul 2012

Eosinophil count predicts mortality risk following heart procedure

Study findings suggest that eosinophil count predicts mortality risk in patients undergoing percutaneous coronary intervention.

12 Jul 2012

AOSSM to present ten research awards and seven grants during annual meeting in Baltimore

In order to recognize and encourage cutting-edge research in key areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine (AOSSM) will present ten research awards and seven grants during its Annual Meeting, July 12-15 in Baltimore, MD. As a leader in orthopaedic sports medicine, AOSSM annually provides more than $350,000 to research initiatives and projects around the country.

12 Jul 2012

Thrombopoietin mimetic offers aplastic anemia hope

Eltrombopag significantly improves blood counts in some patients with refractory severe aplastic anemia, suggests research published in The New England Journal of Medicine.

11 Jul 2012

Eosinophil count predicts mortality risk following heart procedure

Study findings suggest that eosinophil count predicts mortality risk in patients undergoing percutaneous coronary intervention.

10 Jul 2012

One-quarter of ITP patients achieve 5-year treatment-free response

Approximately 25% of patients with immune thrombocytopenia purpura who receive treatment with rituximab maintain a treatment-free response lasting for at least 5 years, study findings suggest.

10 Jul 2012

Novel biomimetic strategy can dissolve blood clots before they cause serious damage or even death

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a novel biomimetic strategy that delivers life-saving nanotherapeutics directly to obstructed blood vessels, dissolving blood clots before they cause serious damage or even death.

6 Jul 2012

FDC precursor cells exist in the wall of blood vessels

Chronic inflammatory conditions are extremely common diseases in humans and in the entire animal kingdom. Both in autoimmune diseases and pathogen-caused diseases, the inflamed areas are rapidly colonized by antibody producing B lymphocytes - which organize themselves in highly structured areas called "lymphoid follicles".

6 Jul 2012

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

Eltrombopag, a drug that was designed to stimulate production of platelets from the bone marrow and thereby improve blood clotting, can raise blood cell levels in some people with severe aplastic anemia who have failed all standard therapies.

5 Jul 2012

TMC receives NIH grant to evaluate pepducin in heart disease patients

Tufts Medical Center researchers are developing a first-of-its-kind drug to prevent deadly blood clots in heart disease patients, without the risk of serious bleeding associated with current medications. The National Heart, Lung, and Blood Institute of the National Institutes of Health has just awarded the team led by Athan Kuliopulos, MD, PhD, a $10 million grant to start testing a drug based on this novel technology.

4 Jul 2012

Platelet News and Research

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Link between maternal metabolic or psychological stress and obesity in offspring

Study identifies 329 instances of potentially inappropriate prescribing in Irish older patients

VEGF inhibitor fails to improve nonsquamous NSCLC overall survival

Endovascular stroke therapy may prove beneficial in octogenarians

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

T2Hemostasis provides reliable and rapid results when compared to conventional systems

Medica releases EasyCell solution for hematology laboratories

Ticagrelor ‘now on equal footing’ with other antiplatelets

Ticagrelor ‘now on equal footing’ with other antiplatelets

PRP therapy safe and effective method of treatment for athletes with cartilage tears

Eosinophil count predicts mortality risk following heart procedure

AOSSM to present ten research awards and seven grants during annual meeting in Baltimore

Thrombopoietin mimetic offers aplastic anemia hope

Eosinophil count predicts mortality risk following heart procedure

One-quarter of ITP patients achieve 5-year treatment-free response

Novel biomimetic strategy can dissolve blood clots before they cause serious damage or even death

FDC precursor cells exist in the wall of blood vessels

Eltrombopag can raise blood cell levels in some people with severe aplastic anemia

TMC receives NIH grant to evaluate pepducin in heart disease patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News